RU2013122843A - Гликоформы антитела против фолатного рецептора альфа - Google Patents
Гликоформы антитела против фолатного рецептора альфа Download PDFInfo
- Publication number
- RU2013122843A RU2013122843A RU2013122843/10A RU2013122843A RU2013122843A RU 2013122843 A RU2013122843 A RU 2013122843A RU 2013122843/10 A RU2013122843/10 A RU 2013122843/10A RU 2013122843 A RU2013122843 A RU 2013122843A RU 2013122843 A RU2013122843 A RU 2013122843A
- Authority
- RU
- Russia
- Prior art keywords
- amino acid
- acid sequence
- seq
- monoclonal antibody
- internalization
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US39481210P | 2010-10-20 | 2010-10-20 | |
| US61/394,812 | 2010-10-20 | ||
| PCT/US2011/056966 WO2012054654A2 (en) | 2010-10-20 | 2011-10-19 | Anti-folate receptor alpha antibody glycoforms |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2013122843A true RU2013122843A (ru) | 2014-11-27 |
Family
ID=45975873
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2013122843/10A RU2013122843A (ru) | 2010-10-20 | 2011-10-19 | Гликоформы антитела против фолатного рецептора альфа |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20120164137A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2629798A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2014505012A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20140032944A (cg-RX-API-DMAC7.html) |
| CN (1) | CN103347537A (cg-RX-API-DMAC7.html) |
| AU (2) | AU2011317088B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112013009275A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2815080A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL225579A0 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2013004202A (cg-RX-API-DMAC7.html) |
| RU (1) | RU2013122843A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2012054654A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2172487A1 (en) * | 2005-04-22 | 2010-04-07 | Morphotek Inc. | Antibodies with Immune Effector Activity that Internalize in Folate Receptor Alpha-Positive Cells |
| JP6122948B2 (ja) | 2012-05-15 | 2017-04-26 | モルフォテック, インコーポレイテッド | 胃癌の治療のための方法 |
| SG11201500938XA (en) * | 2012-08-31 | 2015-04-29 | Immunogen Inc | Diagnostic assays and kits for detection of folate receptor 1 |
| CN104884617B (zh) | 2012-12-07 | 2019-02-19 | 协和发酵麒麟株式会社 | 抗folr1抗体 |
| US8956830B2 (en) | 2013-03-14 | 2015-02-17 | Momenta Pharmaceuticals, Inc. | Methods of cell culture |
| TWI771890B (zh) | 2013-03-14 | 2022-07-21 | 美商安美基公司 | 用於增加重組蛋白質之甘露糖含量之方法 |
| US9677105B2 (en) | 2013-03-14 | 2017-06-13 | Momenta Pharmaceuticals, Inc. | Methods of cell culture |
| US20140271622A1 (en) * | 2013-03-14 | 2014-09-18 | Momenta Pharmaceuticals, Inc. | Methods of cell culture |
| US9217168B2 (en) | 2013-03-14 | 2015-12-22 | Momenta Pharmaceuticals, Inc. | Methods of cell culture |
| NZ717140A (en) | 2013-08-30 | 2022-05-27 | Immunogen Inc | Antibodies and assays for detection of folate receptor 1 |
| EP2871190A1 (en) * | 2013-11-11 | 2015-05-13 | ATLAB Pharma | Antibody against GD2-O-acetylated ganglioside with pro-apoptotic activity |
| ES2808853T3 (es) | 2014-11-20 | 2021-03-02 | Hoffmann La Roche | Cadenas ligeras comunes y procedimientos de uso |
| RS61010B1 (sr) | 2014-11-20 | 2020-11-30 | Hoffmann La Roche | Bispecifični antigen vezujući molekuli koji aktiviraju t ćelije protiv folr1 i cd3 |
| SG11201704056XA (en) | 2014-11-20 | 2017-06-29 | Hoffmann La Roche | Combination therapy of t cell activating bispecific antigen binding molecules cd3 abd folate receptor 1 (folr1) and pd-1 axis binding antagonists |
| CA2969225C (en) * | 2014-12-01 | 2023-08-22 | Amgen Inc. | Process for manipulating the level of glycan content of a glycoprotein |
| CN122075735A (zh) | 2015-09-17 | 2026-05-26 | 伊缪诺金公司 | 包含抗folr1免疫缀合物的治疗组合 |
| EP3765521A4 (en) | 2018-03-13 | 2022-03-23 | Phanes Therapeutics, Inc. | ANTI-FOLATE RECEPTOR-1 ANTIBODIES AND USES THEREOF |
| KR102275930B1 (ko) * | 2018-03-14 | 2021-07-12 | (주)알테오젠 | Folr1에 특이적으로 결합하는 항체 및 그의 용도 |
| CN118344485B (zh) * | 2024-06-18 | 2024-10-15 | 南京欧凯生物科技有限公司 | 抗叶酸及其结合蛋白复合物的单克隆抗体或其抗原结合片段、其制备方法及应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050054048A1 (en) * | 2003-07-29 | 2005-03-10 | Luigi Grasso | Antibodies and methods for generating genetically altered antibodies with enhanced effector function |
| CA2556027C (en) * | 2004-02-12 | 2015-11-24 | Morphotek, Inc. | Monoclonal antibodies that specifically block biological activity of a tumor antigen |
| BRPI0514068B8 (pt) * | 2004-08-04 | 2021-05-25 | Applied Molecular Evolution Inc | anticorpo anti-cd20, e, composição farmacêutica |
| CN101374545B (zh) * | 2005-04-15 | 2012-03-28 | 免疫基因公司 | 消除肿瘤中的异质或混合细胞群体 |
| EP2172487A1 (en) * | 2005-04-22 | 2010-04-07 | Morphotek Inc. | Antibodies with Immune Effector Activity that Internalize in Folate Receptor Alpha-Positive Cells |
| CN105709237A (zh) * | 2005-12-16 | 2016-06-29 | Ibc 医药公司 | 基于免疫球蛋白的多价生物活性装配体 |
| WO2011116387A1 (en) * | 2010-03-19 | 2011-09-22 | Tetragenetics, Inc. | Production of aglycosylated monoclonal antibodies in ciliates |
-
2011
- 2011-10-19 KR KR1020137012669A patent/KR20140032944A/ko not_active Withdrawn
- 2011-10-19 US US13/277,161 patent/US20120164137A1/en not_active Abandoned
- 2011-10-19 CA CA2815080A patent/CA2815080A1/en not_active Abandoned
- 2011-10-19 EP EP11835098.2A patent/EP2629798A4/en not_active Withdrawn
- 2011-10-19 RU RU2013122843/10A patent/RU2013122843A/ru not_active Application Discontinuation
- 2011-10-19 AU AU2011317088A patent/AU2011317088B2/en not_active Ceased
- 2011-10-19 BR BR112013009275A patent/BR112013009275A2/pt not_active Application Discontinuation
- 2011-10-19 JP JP2013535058A patent/JP2014505012A/ja active Pending
- 2011-10-19 MX MX2013004202A patent/MX2013004202A/es unknown
- 2011-10-19 CN CN2011800503838A patent/CN103347537A/zh active Pending
- 2011-10-19 WO PCT/US2011/056966 patent/WO2012054654A2/en not_active Ceased
-
2013
- 2013-04-04 IL IL225579A patent/IL225579A0/en unknown
-
2016
- 2016-04-04 AU AU2016202082A patent/AU2016202082A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2012054654A3 (en) | 2012-08-02 |
| CN103347537A (zh) | 2013-10-09 |
| AU2011317088A1 (en) | 2013-05-02 |
| MX2013004202A (es) | 2013-10-17 |
| US20120164137A1 (en) | 2012-06-28 |
| EP2629798A2 (en) | 2013-08-28 |
| AU2011317088B2 (en) | 2016-01-21 |
| CA2815080A1 (en) | 2012-04-26 |
| AU2016202082A1 (en) | 2016-04-28 |
| JP2014505012A (ja) | 2014-02-27 |
| BR112013009275A2 (pt) | 2017-06-20 |
| WO2012054654A2 (en) | 2012-04-26 |
| EP2629798A4 (en) | 2014-05-28 |
| KR20140032944A (ko) | 2014-03-17 |
| IL225579A0 (en) | 2013-06-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014505012A5 (cg-RX-API-DMAC7.html) | ||
| AU2025204722A1 (en) | Antibodies and molecules that immunospecifically bind to BTN1A1 and the therapeutic uses thereof | |
| KR102244173B1 (ko) | 세포상해 유도 치료제 | |
| UA130461C2 (uk) | Композиція окиснених варіантів афліберцепту | |
| JP7854991B2 (ja) | 新規の抗lilrb2抗体および誘導体生成物 | |
| IL310938A (en) | Anti-CCR8 antibodies and their uses | |
| PE20140614A1 (es) | Anticuerpos anti-cd79b e inmunoconjugados | |
| CA3055438A1 (en) | Multispecific antibody constructs binding to muc1 and cd3 | |
| US20220144938A1 (en) | Identification and targeting of tumor promoting carcinoma associated fibroblasts for diagnosis and treatment of cancer and other diseases | |
| JP2014505012A (ja) | 抗葉酸受容体アルファ抗体の糖型 | |
| CA3143989A1 (en) | Targeting alpha3beta1 integrin for treatment of cancer and other diseases | |
| CN113728008A (zh) | 抗cd40抗体及其用途 | |
| EP3076980A1 (en) | A method of treating neoplasia | |
| CN121248787B (zh) | 一种人源化抗人muc1单克隆抗体及其应用 | |
| WO2021056025A2 (en) | Anti-epha10 antibodies and methods of use thereof | |
| CN104707136A (zh) | 新型双功能抗体偶联物及其制法和用途 | |
| EP4247496A1 (en) | Anti-cd25 antibodies | |
| CN104651314B (zh) | 获得高产稳定表达细胞克隆的方法及由此获得的抗体分子 | |
| RU2013139743A (ru) | Гуманизированное моноклональное антитело, специфичное к синдекану-1 | |
| JP7599716B2 (ja) | がんおよび他の疾患の診断および処置のための病原性細胞外マトリックスの同定および標的化 | |
| CN107460221A (zh) | 一种降低抗pd‑l1抗体中蛋白聚合物的细胞培养方法 | |
| EP4274617A1 (en) | An agr2xcd3 bispecific engager for the treatment of cancer | |
| WO2022106665A1 (en) | Anti-cd25 antibodies | |
| RU2535982C1 (ru) | Штамм культивируемых гибридных клеток животного mus musculus l. cchfv vd-1-продуцент моноклонального антитела 4g4/b6 к вирусу крым-конго геморрагической лихорадки | |
| WO2026085488A1 (en) | Bispecific antigen binding compositions for targeting solid tumors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20160617 |